NCT00575952 - Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2008

Primary Completion Date

July 16, 2016

Study Completion Date

July 16, 2016

Conditions

Endometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Squamous Cell CarcinomaEndometrial Undifferentiated CarcinomaRecurrent Uterine Corpus CarcinomaStage IIIA Uterine Corpus CancerStage IIIC Uterine Corpus CancerStage IVA Uterine Corpus CancerStage IVB Uterine Corpus Cancer

Interventions

DRUG

Cisplatin

Given IV or IP

DRUG

Doxorubicin Hydrochloride

Given IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Paclitaxel

Given IV or IP

BIOLOGICAL

Pegfilgrastim

Given SC

Trial Locations (9)

44106

Case Western Reserve University, Cleveland

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

06102

Hartford Hospital, Hartford

06050

The Hospital of Central Connecticut, New Britain

08103

Cooper Hospital University Medical Center, Camden

02905

Women and Infants Hospital, Providence

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK